[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"MemorialCare Health System\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":126},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,47,71,98],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100210429","sbrt-boost-for-unfavorable-prostate-cancer-100210429",false,"NCT02016248","SBRT Boost for Unfavorable Prostate Cancer'","Prospective Evaluation of Stereotactic Body Radiotherapy Boost for Unfavorable Localized Prostate Cancer","Inclusion\n\n* Histologically proven prostate adenocarcinoma\n* Biopsy within 12 months of date of registration required except for patients who already meet criteria for enrollment in the high risk arm of the protocol. For these patients, repeat biopsy will be at the discretion of the treating physician. In general, repeat biopsy is recommended for these patients, but is not required if it will not affect the treating physician's management decisions in regards to the care of the patient.\n* Clinical Stage I-IV, MX-M0 (AJCC VERSION 9)\n* M-stage determined by physical exam, CT, MRI, bone scan, PSMA PET\u002FCT, or biopsy.\n* Prostate volume: ≤ 100 cc (recommended not required)\n* Determined using: volume = π\u002F6 x length x height x width\n* Measurement from CT, MRI or ultrasound ≤ 90 days prior to registration.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n* No prior prostatectomy or cryotherapy of the prostate\n* No prior radiotherapy to the prostate or lower pelvis\n* No implanted hardware or other material that would prohibit appropriate treatment planning or treatment delivery, in the investigator's opinion.\n* Completion of patient questionnaires in section 3.7.\n* Consent signed\n\nExclusion\n\n* No prior prostatectomy or cryotherapy of the prostate\n* No prior radiotherapy to the prostate or lower pelvis\n* No implanted hardware or other material that would prohibit appropriate treatment planning or treatment delivery, in the investigator's opinion.","MALE","18 Years",{"count":19,"type":20},150,"ESTIMATED","INTERVENTIONAL",[23],"NA","The purpose of this study is to find out whether giving a short course of focused radiation called an SBRT \"boost\" is a safe and effective way to treat prostate cancer. This boost delivers a high dose of radiation to the prostate in a non-invasive way, similar to what is done with high dose rate (HDR) brachytherapy but without using needles. The study looks at how well this treatment controls the cancer, what side effects it may cause, and how it affects patients' quality of life over time.",[26],"Prostate Cancer",[28,26,29,30,31,32,33],"Boost","Stereotactic Body Radiation","SBRT","Radiosurgery","SABR","Stereotactic Ablative Body Radiotherapy","RECRUITING","2026-03-25",{"date":37,"type":38},"2026-03-30","ACTUAL",{"date":40,"type":38},"2012-06",{"date":42,"type":20},"2029-06",{"name":44,"class":45},"MemorialCare Health System","OTHER",3,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":55,"minAge":17,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},"100377833","immediate-postpartum-glucose-tolerance-testing-100377833","NCT04199676","Immediate Postpartum Glucose Tolerance Testing","Immediate Postpartum Glucose Tolerance Testing Among Gestational Diabetics: A Comparison to the Gold Standard","Inclusion Criteria:\n\n* Pregnant or recently postpartum (postpartum day 0 or 1)\n* ≥ 18 years of age\n* Gestational age ≥34 weeks\n* A1 or A2 gestational diabetes\n\nExclusion Criteria:\n\n* Medical exclusion from completing glucose tolerance testing\n* Steroid administration within 10 days prior to enrollment\n* Chronic steroid use",true,"FEMALE",{"count":57,"type":20},300,"OBSERVATIONAL","The objective of this study is to compare the accuracy of a 2hr glucose tolerance test administered during the postpartum hospitalization with the standard of care glucose tolerance testing (administered at 6 weeks postpartum). The primary hypothesis is that the glucose tolerance test administered in the postpartum period will be accurate and will improve compliance with postpartum testing for gestational diabetics.",[61],"Gestational Diabetes","2025-09-02",{"date":64,"type":38},"2025-09-03",{"date":66,"type":38},"2020-09-01",{"date":68,"type":20},"2026-12-31",{"name":44,"class":45},1,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":77,"minAge":17,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":21,"phases":80,"briefSummary":81,"conditions":82,"keywords":85,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":70},"100497024","analgesia-first-sedation-in-trauma-patients-100497024","NCT05751863","Analgesia-First Sedation in Trauma Patients","Inclusion Criteria:\n\n1. ≥ 18 years of age\n2. Mechanically ventilated with an expected duration of MV ≥ 48h\n3. Initiated continuous sedative\u002Fanalgesic infusions by the ICU team\n4. Patient is a candidate for MV weaning\n\nExclusion Criteria:\n\n1. Admission after resuscitation from cardiac arrest\n2. Significant neurological deficit due to a chronic disorder\n3. History of alcohol dependence and\u002For other illicit drug abuse\n4. Prior administration of continuous sedative\u002Fanalgesic from a transferring institution\n5. Patient receiving neuromuscular blocking agents\n6. Allergy to midazolam, lorazepam, and\u002For propofol","ALL",{"count":79,"type":20},170,[23],"The study's aim is to ascertain the best approach for providing sedation and pain management for patients who have sustained trauma and are requiring respiratory support from a mechanical ventilator. The common approach to patients who need mechanical ventilation is to provide continuous drips of sedatives and pain medicine and awaken the patient once a day to check the brain functions. Another approach is to provide pain medicine and reserve sedatives for only a short duration when needed. The difference between approaches has not been studied in Trauma patients.",[83,84],"Mechanical Ventilation","Respiratory Failure",[86,87,88,89],"Trauma","Analgesia","Sedation","Intubation","2025-07-03",{"date":92,"type":38},"2025-07-09",{"date":94,"type":38},"2023-04-01",{"date":96,"type":20},"2026-09-01",{"name":44,"class":45},{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":55,"minAge":17,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":21,"phases":108,"briefSummary":110,"conditions":111,"keywords":113,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":70},"100510325","phase-2-aspirin-for-postpartum-patients-with-preeclampsia-100510325","NCT05924971","Aspirin for Postpartum Patients With Preeclampsia","Acetylsalicylic Acid for Postpartum Preeclampsia: A Pilot Randomized Trial","ASAPP","Inclusion Criteria:\n\n* Preeclampsia with severe features diagnosed during delivery admission, as defined by ACOG criteria.\n* Pre- and postnatal care provided by the Long Beach Memorial Ob\u002FGyn resident or Maternal-Fetal Medicine clinic.\n\nExclusion Criteria:\n\n* Patient age \\\u003C18 years old\n* Non-English or Non-Spanish speaking\n* Chronic hypertension diagnosed before 20 weeks' gestation\n* Known allergy, prior adverse reaction, or any medical condition in which aspirin is contraindicated (nasal polyps, gastric or duodenal ulcers, history of gastrointestinal bleeding, severe hepatic dysfunction)\n* Aspirin prescribed postpartum for any other medical condition\n* Bleeding disorder\n* Breastfeeding an infant with thrombocytopenia",{"count":107,"type":20},86,[109],"PHASE2","The purpose of this research study is to evaluate the effect of low-dose aspirin on recovery from severe preeclampsia (a high blood pressure disorder of pregnancy) among women who have given birth. We hypothesize that taking aspirin for the first week after giving birth will enhance recovery from preeclampsia by decreasing the levels of a protein called soluble fms-like tyrosine kinase (sFlt-1), which is thought to be a main contributor to the development of preeclampsia, and speeding up return to a normal blood pressure.",[112],"Preeclampsia Postpartum",[114,115,116,117],"Preeclampsia","Postpartum","Aspirin","sFlt-1","2025-06-03",{"date":120,"type":38},"2025-06-06",{"date":122,"type":38},"2023-07-26",{"date":124,"type":20},"2026-12",{"name":44,"class":45},""]